Approval · Notice of Compliance 19033 · 2017
ONCASPAR: Notice of Compliance 19033
Issued February 24, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19033
- Date
- February 24, 2017
- Company
- Baxalta Canada CorporationToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ONCASPAR | 02461900 | Marketed |
Medicinal ingredients
- PEGASPARGASE 750 UNIT per ML